Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoko Takebe

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
Cancer Research|April 17, 2021
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243Yasuhisa Murai, Ukhyun Jo, Junko Murai, et al.
SLAS Discovery : Advancing Life Sciences R & D|February 25, 2025
Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroidsThomas S Dexheimer, Zahra Davoudi, Nathan P Coussens, et al.
Investigational New Drugs|October 10, 2017
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trialDana B Cardin, Laura W Goff, Emily Chan, et al.
Leukemia & Lymphoma|May 15, 2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemiaJennifer R Brown, Bethany Tesar, Lijian Yu, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
Cancer Research Communications|July 23, 2024
Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4Makito Mizunuma, Christophe E Redon, Liton Kumar Saha, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials NetworkJeffrey Abrams, Barbara Conley, Margaret Mooney, et al.
Radiation Research|April 7, 2021
SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma MultiformeDavid Cerna, Bora Lim, Yusuf Adelabu, et al.
Investigational New Drugs|July 18, 2013
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancerWilliam R Schelman, Tabraiz A Mohammed, Anne M Traynor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
Cancer Research|April 17, 2021
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243Yasuhisa Murai, Ukhyun Jo, Junko Murai, et al.
SLAS Discovery : Advancing Life Sciences R & D|February 25, 2025
Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroidsThomas S Dexheimer, Zahra Davoudi, Nathan P Coussens, et al.
Investigational New Drugs|October 10, 2017
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trialDana B Cardin, Laura W Goff, Emily Chan, et al.
Leukemia & Lymphoma|May 15, 2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemiaJennifer R Brown, Bethany Tesar, Lijian Yu, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
Cancer Research Communications|July 23, 2024
Acetalax (Oxyphenisatin Acetate, NSC 59687) and Bisacodyl Cause Oncosis in Triple-Negative Breast Cancer Cell Lines by Poisoning the Ion Exchange Membrane Protein TRPM4Makito Mizunuma, Christophe E Redon, Liton Kumar Saha, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials NetworkJeffrey Abrams, Barbara Conley, Margaret Mooney, et al.
Radiation Research|April 7, 2021
SMAC Mimetic/IAP Inhibitor Birinapant Enhances Radiosensitivity of Glioblastoma MultiformeDavid Cerna, Bora Lim, Yusuf Adelabu, et al.
Investigational New Drugs|July 18, 2013
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancerWilliam R Schelman, Tabraiz A Mohammed, Anne M Traynor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
Pageof 14